NCT04983095 2026-02-17
METRO
Umeå University
Phase NA Recruiting
Clinical Trials
22 trialsNCT06320067 2025-09-26
STAMPEDE2
University College, London
Phase 3 Recruiting
NCT05242744 2025-07-11
FTT PET/CT in Metastatic Prostate Cancer
Abramson Cancer Center at Penn Medicine
Recruiting
NCT02913196 2025-05-23
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Active not recruiting
NCT05457699 2025-03-17
ANCHORProstate
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Recruiting
NCT03413995 2024-10-16
TRIUMPH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04916613 2024-09-26
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
UNICANCER
Phase 3 Recruiting
NCT06251492 2024-02-20
Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)
Fudan University
Phase 2 Unknown
NCT05567770 2023-08-24
ACTION
Weill Medical College of Cornell University
Phase 1 Withdrawn
NCT03223727 2023-04-18
ROTOR
The Netherlands Cancer Institute
Completed
NCT05627778 2022-11-28
68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis
Peking Union Medical College Hospital
Phase 1/2 Unknown
NCT03434158 2022-11-03
IMANOL
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT05530395 2022-09-14
BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC
University Hospital Virgen de las Nieves
Unknown
NCT02961257 2022-05-12
CABASTY
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 3 Completed
NCT02814968 2022-04-14
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT02815033 2022-04-14
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The European Uro-Oncology Group
Phase 2 Completed
NCT05078151 2021-10-14
iPROMET
Vall d'Hebron Institute of Oncology
Phase NA Unknown
NCT03024216 2021-05-26
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
University of Hawaii
Phase 1 Completed
NCT04660617 2021-05-11
A Multi-omics Study of Metastatic Prostate Cancer (MOSMPCA)
West China Hospital
Unknown
NCT04824937 2021-04-01
Telaglenastat + Talazoparib In Prostate Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT02964988 2019-10-15
uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Rigshospitalet, Denmark
Phase 2 Terminated
NCT03414437 2019-03-19
Post-eRADicAte
Carolina Research Professionals, LLC
Unknown